Interaction between HIV-1 and APOBEC3 sub-family of proteins

Current HIV Research

Volumn 4, Issue 4, 2006, Pages 401-409

  Arriaga, Maria E ^a   Carr, Jillian ^b   Li, Peng ^b   Wang, Bin ^a   Saksena, Nitin K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Activated CD4; APOBEC3A; Cytidine deaminases; HIV replication; Vif interaction

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE DEAMINASE; GAG PROTEIN; NUCLEOCAPSID PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS DNA; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INNATE IMMUNITY; LENTIVIRINAE; LYMPHOCYTE ACTIVATION; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN INTERACTION; RETROVIRUS INFECTION; REVIEW; VIRION; VIRUS MUTATION; VIRUS REPLICATION;

CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; GENE PRODUCTS, VIF; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33749538587     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016206778560063     Document Type: Review

References (78)

1. Alce TM, Popik W. (2004). APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. Journal of Biological Chemistry. 279: 34083-34086.
2. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, Trono D, Vlahov D, Donfield S, Goedert J, Phair J, Buchbinder S, O'Brien SJ, Telenti S, Winkler CA. (2004). APOBEC3G genetic variants and their influence on the progression to AIDS. Journal of Virology. 78: 11070-11076.
3. Berkhout B, Das AT, Beerens N. (2001). HIV-1 RNA editing, hypermutation, and error-prone reverse transcription. Science. 292: 73.
4. Berkhout B, de Ronde. (2004). APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS. 18(13): 1861-1863.
5. Berkowitz RD, Ohagen A, Höglund S, Goff SP. (1995). Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polyproteins during RNA packaging in vivo. Journal of Virology. 69: 6445:6456.
6. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. (2004). Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Current Biology. 14: 1392-1396.
7. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. (2004). A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proceeding of the National Academy of Science Unites States of America. 101: 3770-3774.
8. Borman AM, Quillent C, Charmeau P, Kean KM, Clavel F. (1995). A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinats in G→A hypermutation during negative-strand viral DNA synthesis. Virology. 208: 601-609.
9. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC. (2004). CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. Journal of Experimental Medicine. 200(6): 749-759.
10. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L. (2004). The interaction between HIV-1 Gag and APOBEC3G. Journal of Biological Chemistry. 279: 33177-33184.
11. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. (2005). Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature. 435: 108-114.
12. Cho SJ, Drechsler H, Burke RC, Arens MQ, Powderly W, Davidson NO. (2006). APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. Journal of Virology. 80(4): 2069-2072.
13. Conticello SG, Harris RS, Neuberger MS. (2003). The vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Current Biology. 13: 2009-2013.
14. Cullen BR. (2006). Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. Journal of Virology. 80: 1067-1076.
15. Delebecque F, Suspene R, Calattini S, Casartelli N, Saib A, Froment A, Wain-Hobson S, Gessain A, Vartanian JP, Schwartz O. (2006). Restriction of foamy viruses by APOBEC cytidine deaminases. Journal of Virology. 80: 605-614.
16. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, Arthur LO, Johnson RP. (1998). Identification of highly attenuated mutants of simian immunodeficiency virus. Journal of Virology. 72: 1431-1437.
17. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. (2000). Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. Jouranl of Virology. 74: 8938-8945.
18. Doehle BP, Schäfer A, Cullen BR. (2005). Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology. 339: 281-288.
19. Douaisi M, Dussart S, Courcoul M, Bessou G, Vigne R, Decroly E. (2004). HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochemical and Byophysical Research Communication. 321: 566-573.
20. Fitzgibbon JE, Mazar S, Dubin T. (1993). A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Research and Human Retroviruses. 9: 833-838.
21. Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, Beer BE, Marx PA, Gao F, Bibollet-Ruche F, Hahn BH, Malim MH. (2004). Further investigation of simian immunodeficiency virus Vif function in human cells. Journal of Virology. 78: 12041-12046.
22. Gao F, Chen Y, Levy DN, Conway JA, Kepler TB, Hui H. (2004). Unselected mutations in the human immunodeficiency virus1 genome are mostly non synonymous and often deleterious. Jouranl of Virology. 78: 2426-2433.
23. Goff SP. (2003). Death by deamination: a novel host restriction system for HIV-1. Cell. 114: 281-283.
24. Goncalves J, Sant-Marta M. (2004). HIV-1 vif and APOBEC3G: Multiple roads to one goal. Retrovirology. 1:28.
25. Harris RS, Bishop N, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. (2003). DNA deamination mediates innate immunity to retroviral infection. Cell. 113: 803-809.
26. Harris RS, Liddament MT. (2004). Retroviral restriction by APOBEC proteins. Nature Reviews Immunology. 4: 868-877.
27. Huthoff H, Malin H. (2005). Cytidine deamination and resistance to retroviral infection: Towards a structural understanding of the APOBEC proteins. Virology. 334: 147-153.
28. Janini M, Rogers M, Birx DR, McCutchan FE. (2001). Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. Journal of Virology. 75: 7973-7986.
29. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. (2002). An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 79: 285-296.
30. Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H. (2005). APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. Journal of Virology. 79: 11513-11516.
31. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. (2003). The human immunodeficiency virus type 1 vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. Journal of Virology. 77: 11398-11407.
32. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. (2004). Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology. 1: 27.
33. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow G, Ly H, Strebel K. (2005). Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. Journal of Virology. 79: 5870-5874.
34. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. (2004). G→A Hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. Jouranl of Virology. 79: 1975-1980.
35. Kile BT, Schulman BA, Alexander WS, Nicole NA, Martin HM, Hilton DJ. (2002). The SOCS box: a tale of destruction and degradation. Trends in Biochemical Sciences. 27: 235-241.
36. Langlois MA, Beale RC, Conticello SG, Neuberger MS. (2005). Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/ G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Research. 33: 1913-1923.
37. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. (2003). Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300: 1112.
38. Lee GS, Brant VL, Roth DB. (2004). B cell development leads off with a base hit: dU:dG mismatches in class switching and hypermutation. Molecular Cell. 16: 505-508.
39. Lee TH., Coligan JE, Allan JS, McLane MF, Groopman JE, Essex M. (1986). A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science. 231: 1546-1549.
40. Liao W, Hong SH, Chan BH, Rudolph FB, Clark SC, Chan L. (1999). APOBEC-2, a cardiac and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochemical and Byophysical Research Communication. 260: 398-404.
41. Liddament MT, Brown WL, Schumacher AJ, Harris RS. (2004). APOBEC3F properties and hypermutation prefernces indicate activity against HIV-1 in vivo. Current Biology. 14: 1385-1391.
42. Liu B, Yu X, Luo K, Yu Y, Yu XF. (2004). Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. Journal of Virology. 78: 2072-2081.
43. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S. (2000). Analysis of human immunodeficiency virus type 1 g160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. Journal of Neurovirology. 6(Suppl. 1): S70-S81.
44. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF. (2004). Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. Journal of Virology. 78: 11841-11852.
45. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
46. Mangeat B, Turelli P, Liao S, Trono D. (2004). A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. Journal of Biological Chemistry. 279: 14481-14483.
47. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. (2003). Species-specific exclusion of APOBEC3G from HIV-1 virions by vif. Cell. 114: 21-31.
48. Marin M, Rose KM, Kozak SL, Kabat D. (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Natural Medicine. 11: 1398-1403.
49. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. (2004). Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. Journal of Biological Chemistry. 279: 7792-7798.
50. Michaels FH, Hattori N, Gallo RC, Franchini G. (1993). The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2. AIDS Research of Human Retroviruses. 9: 1025:1030.
51. Monken CE, Wu B, Srinivasan A. (1995). High resolution analysis of HIV-1 quasispecies in the brain. AIDS. 9: 345-349.
52. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. (2005). Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current Biology. 15: 166-170.
53. Pham P. Bransteitter R, Goodman MF. (2005). Reward versus risk: DNA cytidine deaminases triggering immunity and disease. Biochemistry. 44: 2703-2715.
54. Rose KM, Marin M, Kozak SL, Kabat D. (2005). Regulated production and anti-HIV typel activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Research and Human Retroviruses. 21: 611-619.
55. Schäfer A, Bogerd HP, Cullen BR. (2004). Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology. 328:163-168.
56. Schrofelbauer B, Chen D, Landau NR. (2004). A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proceeding National Academy of Science United States of America. 101: 3927-3932.
57. Sheehy AM, Gaddis NC, Choi JD, Malim MH. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418: 646-650.
58. Sheehy AM, Gaddis NC, Malim MH. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Medicine. 9: 1404-1407.
59. Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T. (2003). The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. Journal of Biological Chemistry. 278: 44412-44416.
60. Simon V, Zennou V, Murray D, Hunag Y, Ho DD, Bieniasz PD. (2005). Natural variation in vif: differential impact on APOBEC3G/F and a potential role in HIV-1 diversification. PLoS Pathogens. 1: e6.
61. Sova P, Volsky DJ. (1993). Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. Virology. 67: 6322-6326.
62. Stopak K, de Noronha C, Yonemoto W, Greene WC. (2003). HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell. 12: 591-601.
63. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. (2005). Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine daminases in vitro and in vivo. Proceeding of the National Academy of Science United States of America. 102: 8321-8326.
64. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK. (2004). Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC 3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. Journal of Biological Chemistry. 279: 35822-35828.
65. Teng B., Burant CF, Davidson NO. (1993). Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260: 1816-1819.
66. Van Hemert FJ, Berkhout B. (1995). The tendency of lentiviral open reading frames to become A-rich: constraints imposed by viral genome organization and cellular tRNA availability. Journal of Molecular Evolution. 41: 132-140.
67. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. (1991). Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. Journal of Virology. 65: 1779-1788.
68. Wang B, Mikhail M, Dyer WB, Zaunders JJ, Kelleher AD, Saksena N. (2003). First demonstration of a lack of viral sequence evolution in a nonprogresor, defining replication-incompetent HIV-1 infection. Virology. 312: 135-150.
69. Wei M, Xing H, Hong K, Huang H, Tang H, Qin G, Shao Y. (2004). Biased G-to-A hypermutation in HIV-1 proviral DNA from a long-term non-progressor. AIDS. 18: 1863-1865.
70. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. (2004). A second human antiretroviral factor, APOBEC3F is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO Journal. 23: 2451-2458.
71. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR. (2004). APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. Journal of Biological Chemistry. 279: 53379-53386.
72. Yu Q, König R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. (2004). Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nature Structural & Molecular Biology. 11: 435-442.
73. Yu X, Yu Y, Liu B, Luo K, Wong W, Mao P, Yu XF. (2003). Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 302: 1056-1060.
74. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 424: 94-98.
75. Zhang J, Webb DM. (2004). Rapid evolution of primate antiviral enzyme APOBEC3G. Human Molecular Genetics. 13: 1785-1791.
76. Zheng YH., Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. (2004). Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. Journal of Virology. 78: 6073-6076.
77. Zennou V, Bieniasz PD. (2006). Comparative analysis of the antiretroviral activity of APOBEC3G and 3F from primates. Virology. 349: 31-40.
78. Zennou V, Perez-Caballero D, Göttlinger H, Bieniasz PD. (2004). APOBEC3G incorporation into human immunodeficiency virus type 1 particles. Journal of Virology. 78: 12058-12061.